Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12622000902796
ACTRN12622000902796
Not yet recruiting
未知

Feasibility and preliminary efficacy of N-Acetylcysteine for loss of control eating: an open-label study

Florey Institute of Neuroscience and Mental Health0 sites36 target enrollmentJune 24, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsloss of control eatingMental Health - Eating disorders

Overview

Phase
未知
Intervention
Not specified
Conditions
loss of control eating
Sponsor
Florey Institute of Neuroscience and Mental Health
Enrollment
36
Status
Not yet recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 24, 2022
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Florey Institute of Neuroscience and Mental Health

Eligibility Criteria

Inclusion Criteria

  • •Adult (age \>18 years) with loss of control eating, defined as at least one episode of loss of control eating in the past month as assessed using the Eating Loss of Control Scale
  • •\- Negative pregnancy test at baseline for participants of childbearing potential

Exclusion Criteria

  • •\- Participant with cognitive impairment which will hinder their ability to provide informed consent or to complete the surveys
  • •\- Participants who are pregnant or lactating or planning to become pregnant during the study
  • •\- Use of any medication containing N\-Acetylcysteine or other contraindicated medications within 4 weeks prior to enrolment,
  • •\- Known previous hypersensitivity to N\-Acetylcysteine
  • •\- Any serious medical illness that N\-Acetylcysteine may adversely affect.
  • •\- Surgery within the past 28 days
  • •\- Currently using or planning to use a formal weight loss program during the study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
Investigating the efficacy and safety of N-Acetyl Cysteine (NAC) inhalation spray in controlling the symptoms of patients with COVID-19
IRCT20080901001165N55Bagheiat-allah University of Medical Sciences250
Recruiting
Phase 3
Evaluation of N-Acetyl Cysteine mouthwash in preventing the occurrence of chemotherapy-induced oral mucositischemotherapy-induced oral mucositis.Oral mucositis (ulcerative)K12.3
IRCT20220712055439N1Mazandaran University of Medical Sciences68
Active, not recruiting
Phase 1
Efficacy and safety of the combination of acetylcysteine, paracetamol and phenylephrine for the treatment of common cold
EUCTR2021-002058-96-PLek Pharmaceuticals d.d.1,002
Active, not recruiting
Phase 1
Efficacy and safety of the combination of acetylcysteine, paracetamol and phenylephrine for the treatment of common coldCommon cold and flu-like infectionsMedDRA version: 22.1Level: LLTClassification code 10010106Term: Common coldSystem Organ Class: 100000004862MedDRA version: 20.1Level: LLTClassification code 10000938Term: Acute nasopharyngitis (common cold)System Organ Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2021-002058-96-BGek Pharmaceuticals d.d.1,002
Completed
Phase 2
Comparing therapeutic efficacy of N-acetyl cysteine with the combination of N-acetyl cysteine and Cimetidine in acute acetaminophen toxicityAcute acetaminophen toxicity.Poisoning by drugs, medicaments and biological substancesT36, T37,
IRCT2013102915204N1Vice chancellor for research, Mashhad University of Medical Sciences30